538 related articles for article (PubMed ID: 28506291)
21. B cell TLR1/2, TLR4, TLR7 and TLR9 interact in induction of class switch DNA recombination: modulation by BCR and CD40, and relevance to T-independent antibody responses.
Pone EJ; Lou Z; Lam T; Greenberg ML; Wang R; Xu Z; Casali P
Autoimmunity; 2015 Feb; 48(1):1-12. PubMed ID: 25536171
[TBL] [Abstract][Full Text] [Related]
22. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
23. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
Rossi EA; Chang CH; Goldenberg DM
PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
[TBL] [Abstract][Full Text] [Related]
24. CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity.
Clark EA; Giltiay NV
Front Immunol; 2018; 9():2235. PubMed ID: 30323814
[TBL] [Abstract][Full Text] [Related]
25. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
[TBL] [Abstract][Full Text] [Related]
26. Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease.
Rip J; de Bruijn MJW; Appelman MK; Pal Singh S; Hendriks RW; Corneth OBJ
Front Immunol; 2019; 10():95. PubMed ID: 30761150
[TBL] [Abstract][Full Text] [Related]
27. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus.
Jenks SA; Cashman KS; Zumaquero E; Marigorta UM; Patel AV; Wang X; Tomar D; Woodruff MC; Simon Z; Bugrovsky R; Blalock EL; Scharer CD; Tipton CM; Wei C; Lim SS; Petri M; Niewold TB; Anolik JH; Gibson G; Lee FE; Boss JM; Lund FE; Sanz I
Immunity; 2018 Oct; 49(4):725-739.e6. PubMed ID: 30314758
[TBL] [Abstract][Full Text] [Related]
28. Epratuzumab for the treatment of systemic lupus erythematosus.
Geh D; Gordon C
Expert Rev Clin Immunol; 2018 Apr; 14(4):245-258. PubMed ID: 29542345
[TBL] [Abstract][Full Text] [Related]
29. Toll-like receptor 7 agonist imiquimod prevents the progression of SLE in MRL/lpr mice via inhibiting the differentiation of T follicular helper cells.
Duan X; Shen C; Zhang X; Wu L; Chen J; Ma B; Wang Q; Sun P; Lan Y; Su C
Int Immunopharmacol; 2020 Mar; 80():106239. PubMed ID: 32007709
[TBL] [Abstract][Full Text] [Related]
30. CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.
Matsubara N; Imamura A; Yonemizu T; Akatsu C; Yang H; Ueki A; Watanabe N; Abdu-Allah H; Numoto N; Takematsu H; Kitazume S; Tedder TF; Marth JD; Ito N; Ando H; Ishida H; Kiso M; Tsubata T
Front Immunol; 2018; 9():820. PubMed ID: 29725338
[TBL] [Abstract][Full Text] [Related]
31. TLR7- and TLR9-responsive human B cells share phenotypic and genetic characteristics.
Simchoni N; Cunningham-Rundles C
J Immunol; 2015 Apr; 194(7):3035-44. PubMed ID: 25740945
[TBL] [Abstract][Full Text] [Related]
32. Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus.
Rivellese F; Manou-Stathopoulou S; Mauro D; Goldmann K; Pyne D; Rajakariar R; Gordon P; Schafer P; Bombardieri M; Pitzalis C; Lewis MJ
Lupus Sci Med; 2021 Mar; 8(1):. PubMed ID: 33727237
[TBL] [Abstract][Full Text] [Related]
33. IFNγ induces epigenetic programming of human T-bet
Zumaquero E; Stone SL; Scharer CD; Jenks SA; Nellore A; Mousseau B; Rosal-Vela A; Botta D; Bradley JE; Wojciechowski W; Ptacek T; Danila MI; Edberg JC; Bridges SL; Kimberly RP; Chatham WW; Schoeb TR; Rosenberg AF; Boss JM; Sanz I; Lund FE
Elife; 2019 May; 8():. PubMed ID: 31090539
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells.
Nakou M; Papadimitraki ED; Fanouriakis A; Bertsias GK; Choulaki C; Goulidaki N; Sidiropoulos P; Boumpas DT
Clin Exp Rheumatol; 2013; 31(2):172-9. PubMed ID: 23137515
[TBL] [Abstract][Full Text] [Related]
35. Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients.
Rodríguez-Bayona B; Ramos-Amaya A; Pérez-Venegas JJ; Rodríguez C; Brieva JA
Arthritis Res Ther; 2010; 12(3):R108. PubMed ID: 20525218
[TBL] [Abstract][Full Text] [Related]
36. Anergic responses characterize a large fraction of human autoreactive naive B cells expressing low levels of surface IgM.
Quách TD; Manjarrez-Orduño N; Adlowitz DG; Silver L; Yang H; Wei C; Milner EC; Sanz I
J Immunol; 2011 Apr; 186(8):4640-8. PubMed ID: 21398610
[TBL] [Abstract][Full Text] [Related]
37. Signals from activation of B-cell receptor with anti-IgD can override the stimulatory effects of excess BAFF on mature B cells in vivo.
Nguyen TG; Morris JM
Immunol Lett; 2014 Sep; 161(1):157-64. PubMed ID: 24954638
[TBL] [Abstract][Full Text] [Related]
38. Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.
Steinfeld SD; Youinou P
Expert Opin Biol Ther; 2006 Sep; 6(9):943-9. PubMed ID: 16918261
[TBL] [Abstract][Full Text] [Related]
39. A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation.
Månsson A; Adner M; Höckerfelt U; Cardell LO
Immunology; 2006 Aug; 118(4):539-48. PubMed ID: 16780564
[TBL] [Abstract][Full Text] [Related]
40. A novel epitope from CD22 regulates Th1 and Th17 cell function in systemic lupus erythematosus.
Yuan J; Yu M; Cao AL; Chen X; Zhang LH; Song Y; Cheng X; Zhou ZH; Wang M; Guo HP; Du R; Liao YH
PLoS One; 2013; 8(5):e64572. PubMed ID: 23704998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
